Nanjing Chest Hospital
Listed for 1 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Nanjing Chest Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Lung cancer
肺癌Led 25 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
8 hospitals in Nanjing for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06892548
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou
- RecruitingA Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07143045
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led25
- Three-Dimensional Computed Tomography Reconstruction in Uniportal Thoracoscopic Segmentectomy: A Propensity Score-matched Analysis.
- Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50.
- Clinical Efficacy and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Squamous Cell Lung Cancer: A Retrospective Single-Center Study in China.
- The impact of EGFR-TKIs treatment on ground-glass opacity-featured lung adenocarcinama.
- UBE2Q1 as a novel cancer biomarker for lung adenocarcinoma.
- Indocyanine green fluorescence identification of the intersegmental plane by the target segmental vein-first single-blocking during thoracoscopic segmentectomy.
- Silencing of ZNF610 suppresses cell proliferation and migration in lung adenocarcinoma.
- TFR1-Mediated Iron Metabolism Orchestrates Tumor Ferroptosis and Immunity in Non-Small Cell Lung Cancer.
- Targeting TRIM9 by miR-218-5p Restricts Cell Proliferation and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.
- Real-time image-guided indocyanine green fluorescence dual-visualization technique to measure the intraoperative resection margin during thoracoscopic segmentectomy.
- The D ~ Sense ex-vivo viability assay application in a patient with stage IV lung adenocarcinoma: a case report.
- Circular RNA-microRNA-mRNA network identified circ_0007618 and circ_0029426 as new valuable biomarkers for lung adenocarcinoma.
- Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.
- Echinacoside Induces Mitochondria-Mediated Pyroptosis through Raf/MEK/ERK Signaling in Non-Small Cell Lung Cancer Cells.
- A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma.
- Diagnostic value of endobronchial ultrasound combined with rapid on-site evaluation of transbronchial lung biopsy for peripheral pulmonary lesions.
- Serum tumour M2-pyruvate kinase as a biomarker for diagnosis and prognosis of early-stage non-small cell lung cancer.
- Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer.
- Alginic acid inhibits non-small cell lung cancer-induced angiogenesis via activating miR-506 expression.
- Concurrent vs sequential chemoradiotherapy for patients with advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.
- Challenges in Advanced Lung Cancer Diagnosis During the COVID-19 Pandemic.
- Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience.
- Improved diagnostic yield of transbronchial lung biopsy in peripheral pulmonary lesions using a combination of endobronchial ultrasound and rapid on-site evaluation.
- Clinical significance of intrapulmonary lymph node dissection in pathological stage IA non-small cell lung cancer: A propensity score matching analysis.
- Feasibility investigation of near-infrared fluorescence imaging with intravenous indocyanine green method in uniport video-assisted thoracoscopic anatomical segmentectomy for identifying the intersegmental boundary line.
All its trials on ClinicalTrials.gov, any status13
- A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
- Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
- Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
- A Study of AL8326 in Non-Small Cell Lung Cancer
- A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
- Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
- A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
- Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR
Getting in touch
Name card to show staff or a driver
Nanjing Chest Hospital
南京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.